Home > Insider Trading > Filing (0001246360-15-001760)

Filing Details

Accession Number:: 0001246360-15-001760
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-04-09 17:21:09
Reporting Period:: 2015-04-07

Filing Date:: 2015-04-09
Accepted Time:: 2015-04-09 17:21:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559209	Glen Williams	33 Hayden Ave Lexington MA 02421	Svp, Technical Operations	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-04-07	85	$76.88	468	No	4	A	Direct
Common Stock	Acquisiton	2015-04-07	2,769	$40.32	3,237	No	4	M	Direct
Common Stock	Disposition	2015-04-07	2,769	$96.04	468	No	4	S	Direct
Common Stock	Acquisiton	2015-04-08	15,263	$40.32	15,731	No	4	M	Direct
Common Stock	Acquisiton	2015-04-08	24,600	$57.56	40,331	No	4	M	Direct
Common Stock	Disposition	2015-04-08	39,863	$96.08	468	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-04-07	2,769	$0.00	2,769	$40.32
Common Stock	Stock Option (Right to Buy)	Disposition	2015-04-08	15,263	$0.00	15,263	$40.32
Common Stock	Stock Option (Right to Buy)	Disposition	2015-04-08	24,600	$0.00	24,600	$57.56

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
36,931	2023-06-06	No	4	M	Direct
21,668	2023-06-06	No	4	M	Direct
15,000	2022-10-04	No	4	M	Direct

Footnotes

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Synageva BioPharma Corp. Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2014 through December 31, 2014. This transaction is also exempt under Rule 16b-3(c).
The reporting person is voluntarily reporting this transaction as of April 7, 2015, but the actual transaction took place on December 31, 2014, the last trading day of the option period under the ESPP.
In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on July 1, 2014, the first trading day of the option period.
The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2015.
25% of the total number of shares subject to the option vest and become exercisable on 06/06/2014 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.00 to $96.18. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
25% of the total number of Shares subject to the option vest and become exercisable on 09/24/2013 and 1/36 of the remainder of the Shares subject to the option shall vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.00 to $96.71. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.